Welcome to our dedicated page for Wuxi Apptec news (Ticker: WUXAY), a resource for investors and traders seeking the latest updates and insights on Wuxi Apptec stock.
WuXi AppTec Co., Ltd. (WUXAY) is a global leader in pharmaceutical R&D and manufacturing services, providing critical support for drug discovery through its integrated CRDMO and CTDMO platforms. This news hub offers investors and industry professionals centralized access to essential updates shaping the company's position in life sciences innovation.
Track official press releases covering clinical trial milestones, regulatory approvals, and strategic partnerships. Our curated news collection includes earnings reports, manufacturing capacity expansions, and technological advancements across small-molecule and biologics development. Key updates span: quarterly financial results, global facility certifications, novel therapy collaborations, and operational efficiency initiatives.
This resource enables stakeholders to monitor WuXi AppTec's progress in accelerating drug development timelines while maintaining compliance with international quality standards. Regular updates reflect the company's role in enabling cost-effective solutions for 6,000+ clients across 30 countries.
Bookmark this page for real-time notifications on material developments impacting pharmaceutical services markets. Combine these updates with fundamental analysis tools available through Stock Titan for comprehensive investment decision-making.
WuXi AppTec reported a 5.8% increase in revenue year-over-year, reaching
WuXi AppTec reported a 71.8% increase in revenue year-over-year, reaching RMB39,355 million for 2022. Their net profit attributable to owners grew 72.9% to RMB8,814 million, with diluted EPS rising 63.0% to RMB2.82. The adjusted non-IFRS net profit surged 83.2% to RMB9,399 million. Operating cash flow improved by 133.6% to RMB10,230 million, with free cash flow turning positive. A cash dividend of RMB2,644 million will be distributed, constituting 30% of 2022 net profit. Despite challenges from COVID-19, WuXi expanded its customer base to over 5,950 active accounts, driving strong performance in its CRDMO and CTDMO business models.
WuXi AppTec has been awarded the 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award by Frost & Sullivan, marking its sixth consecutive recognition. The award highlights WuXi AppTec's leadership and innovative services in the pharmaceutical and biotech sectors. The company's integrated CRDMO and CTDMO models enhance customer service value and address evolving healthcare demands. WuXi AppTec aims to strengthen its capabilities to support the development of groundbreaking therapies for patients worldwide.
WuXi AppTec reported a remarkable performance for Q3 2022, achieving a 77.8% year-over-year increase in revenue to RMB10,638 million. The net profit attributable to owners soared 209.1% year-over-year to RMB2,742 million, with diluted EPS rising 170.0% to RMB0.81. For the nine months ending September 30, 2022, revenue increased 71.9% year-over-year to RMB28,395 million, while net profit grew 107.1% to RMB7,378 million. Operating cash flow surged 142.1% to RMB7,431 million, showcasing robust operational execution.
FAQ
What is the current stock price of Wuxi Apptec (WUXAY)?
What is the market cap of Wuxi Apptec (WUXAY)?
